Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients.
Arisi I, Malimpensa L, Manzini V, Brandi R, Gosetti di Sturmeck T, D'Amelio C, Crisafulli S, Ferrazzano G, Belvisi D, Malerba F, Florio R, Pascale E, Soreq H, Salvetti M, Cattaneo A, D'Onofrio M, Conte A. Arisi I, et al. Among authors: malimpensa l. Front Immunol. 2023 Dec 13;14:1234869. doi: 10.3389/fimmu.2023.1234869. eCollection 2023. Front Immunol. 2023. PMID: 38152407 Free PMC article.
Frailty and relapse activity in multiple sclerosis: A longitudinal observation.
Baione V, Canevelli M, Belvisi D, Buscarinu MC, Bellucci G, Fantozzi R, Nicoletti CG, Malatuni G, Cortese A, De Giglio L, Tartaglia M, Ferrazzano G, Malimpensa L, Leodori G, Bruno G, Ferraro E, Marfia GA, Centonze D, Salvetti M, Conte A. Baione V, et al. Among authors: malimpensa l. Mult Scler Relat Disord. 2023 Apr;72:104603. doi: 10.1016/j.msard.2023.104603. Epub 2023 Mar 5. Mult Scler Relat Disord. 2023. PMID: 36905818
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine.
Dominelli F, Zingaropoli MA, Tartaglia M, Tortellini E, Guardiani M, Perri V, Pasculli P, Ciccone F, Malimpensa L, Baione V, Napoli A, Gaeta A, Lichtner M, Conte A, Mastroianni CM, Ciardi MR. Dominelli F, et al. Among authors: malimpensa l. Front Immunol. 2022 Dec 1;13:1050183. doi: 10.3389/fimmu.2022.1050183. eCollection 2022. Front Immunol. 2022. PMID: 36532061 Free PMC article.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP; CladStop study group. Schiavetti I, et al. Among authors: malimpensa l. Eur J Neurol. 2024 Jun;31(6):e16250. doi: 10.1111/ene.16250. Epub 2024 Mar 28. Eur J Neurol. 2024. PMID: 38549186
Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk.
Zingaropoli MA, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A, Perri V, Malimpensa L, Ferrazzano G, Iannetta M, Del Borgo C, Lichtner M, Mastroianni CM, Conte A, Ciardi MR. Zingaropoli MA, et al. Among authors: malimpensa l. Biology (Basel). 2023 Apr 12;12(4):587. doi: 10.3390/biology12040587. Biology (Basel). 2023. PMID: 37106787 Free PMC article.